From reprogrammed stem cells to next-generation gene editing, 2024 has seen some incredible developments with the potential to become new treatments.

Pain has really been out of favor in the industry up until very recently,” said John Mulcahy, SiteOne Therapeutics’ CEO. The ...

Button and coin cell batteries can cause serious injuries if ingested or inserted into the nose or ear, and parents are ...

Remedy Plan Therapeutics has commenced dosing in a randomised Phase I trial of hyperbolic NAMPT inhibitor, RPT1G, for cancers.

The Company will focus resources on advancing its lead asset, PYX-201 - PYX-201 is a novel first-in-concept antibody-drug conjugate (ADC) where significant RECIST responses were seen in head and neck ...

Summit Therapeutics (NASDAQ: SMMT) has risen in prominence in the past two years thanks to a promising pipeline candidate, ivonescimab, a potential cancer treatment. It doesn't have a single drug on ...

Remedy Plan Therapeutics, a privately-held clinical-stage pharmaceutical company transforming the field of NAMPT inhibition, announced today the initiation of an adult healthy volunteer Phase 1 ...

Chances are that whenever you take a pill, dab on ointment or have a vaccine, it will have been tested on a humble mouse. But ...

Moderna has struggled in the post-COVID era, making its capacity to generate free cash flows doubtful. See why MRNA stock is ...

Heather Rosentrater, who has spent her entire professional career with the utility, has a firm grasp on the company’s ...

We recently published a list of 10 Best Solar Energy Stocks To Buy Now. In this article, we are going to look at where ...

The abrupt resignation this month of Carlos Tavares, CEO of struggling automaker Stellantis, has focused attention on the ...